MENU
IMUX
AS OF
Dec 24 closing price
Price
$0.58
Change
+$0.01 (+1.75%)
Capitalization
70.28M
55 days until earnings call
Intraday BUY SELL Signals
OUR PRODUCTS
MOBILE APPS
GENERAL INFO
Help
© 2013-2025 All rights reserved. Tickeron Inc.
IMUX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Immunic (IMUX) Ownership - Who owns Immunic?

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis... Show more

#MovingAverage#Momentum#MACD#Pattern#RSI#Stochastic#Aroon#Bollinger

Profile

Industry
Pharmaceuticals Major
Address
1200 Avenue of the Americas
Phone
+1 332 255-9818
Employees
77
Web
https://www.imux.com

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
70.28M
P/E Ratio
N/A
Total Cash
35.13M
Projected Growth
N/A
Total Debt
792K
Revenue
N/A
Risk (Beta)
2.48
Dividend Yield
N/A
Total Cash/Share
0.29
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price

Fundamentals

IMUX
Capitalization
70.3M
P/E Ratio
N/A
Risk (Beta)
2.48
Dividend Yield
N/A
Total Cash
35.1M
Total Cash/Share
0.29
Total Debt
792K
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
10.5M
P/B Ratio
6.69
Cash Flow
N/A
Earnings
-0.8
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
9K
Current Ratio
1.31
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-105.37M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-195.41
Shares Held By Institutions
175M
Shares Outstanding - Current
120M
Total Liabilities
30.2M
Total Volume MTD
N/A
Value
N/A
Gain YTD
-41.570
View a ticker or compare two or three
GO
VS
Compare
VS
Compare
IMUX
Setup
Setup
Daily Signal:
Description
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. IMUX showed earnings on November 13, 2025. You can read more about the earnings report here.
View AI-Driven Trading for IMUX
A.I. Advisor
published General Information

General Information

a developer of pharmaceuticals and oral therapies for the treatment of chronic inflammatory and autoimmune diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
1200 Avenue of the Americas
Phone
+1 332 255-9818
Employees
77
Web
https://www.imux.com